Ex­clu­sive: For­mer In­ter­cept CMO lands new gig at Q32 Bio, two weeks af­ter leav­ing the NASH biotech

Just two weeks ago, In­ter­cept CMO Ja­son Cam­pagna fol­lowed the biotech’s found­ing CEO out the door to pur­sue oth­er op­por­tu­ni­ties, per an SEC fil­ing, as an­a­lysts sense a ma­jor shift tak­ing place at the com­pa­ny. Now, that new op­por­tu­ni­ty has come to light.

Cam­pagna is tak­ing the same CMO po­si­tion at Q32 Bio, the com­pa­ny an­nounced Tues­day morn­ing, join­ing CEO Mike Brox­son’s team in Cam­bridge, MA as they ex­plore the next gen­er­a­tion of com­ple­ment drugs. The move comes af­ter Q32 pulled in two fundrais­ing rounds in 2020 to­tal­ing more than $100 mil­lion and as the biotech is in IND-en­abling stud­ies for its lead pro­gram, dubbed ADX-097.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER